Bellevue Group AG Reduces Position in The Cooper Companies, Inc. (NASDAQ:COO)

Bellevue Group AG lowered its position in The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 10.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 357,130 shares of the medical device company's stock after selling 40,243 shares during the period. Bellevue Group AG owned approximately 0.18% of Cooper Companies worth $32,831,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of the business. Byrne Asset Management LLC purchased a new stake in Cooper Companies in the fourth quarter worth about $33,000. OFI Invest Asset Management acquired a new position in Cooper Companies during the 4th quarter valued at about $34,000. New Age Alpha Advisors LLC purchased a new stake in Cooper Companies in the fourth quarter valued at about $38,000. Covestor Ltd boosted its holdings in Cooper Companies by 35.5% in the fourth quarter. Covestor Ltd now owns 458 shares of the medical device company's stock worth $42,000 after acquiring an additional 120 shares in the last quarter. Finally, West Financial Advisors LLC purchased a new stake in shares of Cooper Companies during the fourth quarter worth about $49,000. Hedge funds and other institutional investors own 24.39% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Stifel Nicolaus reduced their target price on Cooper Companies from $115.00 to $105.00 and set a "buy" rating for the company in a research note on Friday, March 7th. Piper Sandler reaffirmed an "overweight" rating and set a $115.00 target price (down previously from $120.00) on shares of Cooper Companies in a report on Friday, March 7th. JPMorgan Chase & Co. reduced their target price on shares of Cooper Companies from $120.00 to $110.00 and set an "overweight" rating for the company in a report on Friday, March 7th. Robert W. Baird reduced their price objective on Cooper Companies from $117.00 to $107.00 and set an "outperform" rating for the company in a research note on Friday, March 7th. Finally, Needham & Company LLC restated a "hold" rating on shares of Cooper Companies in a research note on Friday, March 7th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $110.25.

Cooper Companies Price Performance

COO stock traded down $0.52 during mid-day trading on Friday, reaching $82.40. 624,096 shares of the company's stock were exchanged, compared to its average volume of 1,440,939. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.91 and a quick ratio of 1.12. The Cooper Companies, Inc. has a 12-month low of $69.81 and a 12-month high of $112.38. The stock's 50 day moving average is $80.71 and its 200 day moving average is $91.19. The company has a market cap of $16.48 billion, a price-to-earnings ratio of 42.26, a price-to-earnings-growth ratio of 2.25 and a beta of 1.08.

Cooper Companies (NASDAQ:COO - Get Free Report) last released its quarterly earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.92. The firm had revenue of $964.70 million for the quarter, compared to analysts' expectations of $981.25 million. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. On average, research analysts expect that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.